Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of $191.64 billion. The enterprise value is $211.06 billion.
| Market Cap | 191.64B |
| Enterprise Value | 211.06B |
Important Dates
The last earnings date was Wednesday, May 6, 2026, before market open.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
Novo Nordisk has 4.44 billion shares outstanding. The number of shares has decreased by -0.20% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.44B |
| Shares Change (YoY) | -0.20% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 28.57% |
| Float | 3.18B |
Valuation Ratios
The trailing PE ratio is 10.19 and the forward PE ratio is 13.65.
| PE Ratio | 10.19 |
| Forward PE | 13.65 |
| PS Ratio | 3.79 |
| Forward PS | 0.64 |
| PB Ratio | 6.12 |
| P/TBV Ratio | 16.98 |
| P/FCF Ratio | 20.38 |
| P/OCF Ratio | 10.49 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.87, with an EV/FCF ratio of 22.45.
| EV / Earnings | 11.22 |
| EV / Sales | 4.17 |
| EV / EBITDA | 7.87 |
| EV / EBIT | 8.47 |
| EV / FCF | 22.45 |
Financial Position
The company has a current ratio of 0.79, with a Debt / Equity ratio of 0.72.
| Current Ratio | 0.79 |
| Quick Ratio | 0.54 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 0.83 |
| Debt / FCF | 2.40 |
| Interest Coverage | 38.38 |
Financial Efficiency
Return on equity (ROE) is 71.40% and return on invested capital (ROIC) is 40.42%.
| Return on Equity (ROE) | 71.40% |
| Return on Assets (ROA) | 19.25% |
| Return on Invested Capital (ROIC) | 40.42% |
| Return on Capital Employed (ROCE) | 48.33% |
| Weighted Average Cost of Capital (WACC) | 5.75% |
| Revenue Per Employee | $727,566 |
| Profits Per Employee | $270,689 |
| Employee Count | 69,505 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 1.17 |
Taxes
In the past 12 months, Novo Nordisk has paid $5.20 billion in taxes.
| Income Tax | 5.20B |
| Effective Tax Rate | 21.66% |
Stock Price Statistics
The stock price has decreased by -39.97% in the last 52 weeks. The beta is 0.35, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -39.97% |
| 50-Day Moving Average | 41.38 |
| 200-Day Moving Average | 48.89 |
| Relative Strength Index (RSI) | 44.93 |
| Average Volume (20 Days) | 14,242,713 |
Short Selling Information
The latest short interest is 21.72 million, so 0.68% of the outstanding shares have been sold short.
| Short Interest | 21.72M |
| Short Previous Month | 17.02M |
| Short % of Shares Out | 0.68% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.21 |
Income Statement
In the last 12 months, Novo Nordisk had revenue of $50.57 billion and earned $18.81 billion in profits. Earnings per share was $4.23.
| Revenue | 50.57B |
| Gross Profit | 42.07B |
| Operating Income | 24.91B |
| Pretax Income | 24.02B |
| Net Income | 18.81B |
| EBITDA | 26.82B |
| EBIT | 24.91B |
| Earnings Per Share (EPS) | $4.23 |
Balance Sheet
The company has $3.34 billion in cash and $22.58 billion in debt, with a net cash position of -$19.25 billion or -$4.33 per share.
| Cash & Cash Equivalents | 3.34B |
| Total Debt | 22.58B |
| Net Cash | -19.25B |
| Net Cash Per Share | -$4.33 |
| Equity (Book Value) | 31.33B |
| Book Value Per Share | 7.05 |
| Working Capital | -7.38B |
Cash Flow
In the last 12 months, operating cash flow was $18.27 billion and capital expenditures -$8.95 billion, giving a free cash flow of $9.40 billion.
| Operating Cash Flow | 18.27B |
| Capital Expenditures | -8.95B |
| Depreciation & Amortization | 1.93B |
| Net Borrowing | 3.76B |
| Free Cash Flow | 9.40B |
| FCF Per Share | $2.12 |
Margins
Gross margin is 83.20%, with operating and profit margins of 49.25% and 37.20%.
| Gross Margin | 83.20% |
| Operating Margin | 49.25% |
| Pretax Margin | 47.49% |
| Profit Margin | 37.20% |
| EBITDA Margin | 53.04% |
| EBIT Margin | 49.25% |
| FCF Margin | 18.59% |
Dividends & Yields
This stock pays an annual dividend of $1.29, which amounts to a dividend yield of 2.99%.
| Dividend Per Share | $1.29 |
| Dividend Yield | 2.99% |
| Dividend Growth (YoY) | 8.79% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 30.39% |
| Buyback Yield | 0.20% |
| Shareholder Yield | 3.19% |
| Earnings Yield | 9.82% |
| FCF Yield | 4.91% |
Analyst Forecast
The average price target for Novo Nordisk is $46.91, which is 9.30% higher than the current price. The consensus rating is "Buy".
| Price Target | $46.91 |
| Price Target Difference | 9.30% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 0.81% |
| EPS Growth Forecast (3Y) | 0.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 20, 2023. It was a forward split with a ratio of 2:1.
| Last Split Date | Sep 20, 2023 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novo Nordisk has an Altman Z-Score of 4.66 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.66 |
| Piotroski F-Score | 4 |